Moderna’s Flu Vaccine Shows Positive Late-Stage Trial Results
Moderna’s experimental mRNA-based influenze (flu) vaccine produced a stronger immune response than a currently available vaccine in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and COVID vaccine.
Vaccine Safety Dominates Office Visit Concerns
Primary care physicians need considerable help winning the vaccine war given the limited amount of time they have to make their case in the exam room, according to the authors of a new study published online April 15 in the American Journal of Preventive Medicine.
Can Inverse Vaccines Cure Autoimmunity?
While traditional vaccines teach the immune system to fight off foreign invaders, inverse vaccines teach the immune system to ignore its own cells — and may completely reverse autoimmune disease.
Avian Flu and Human Vaccines: Where Things Stand
Shortages and recent spikes in egg prices have boosted public awareness that a “bird flu” is devastating domestic poultry flocks across the country. Since its arrival in the U.S. in January 2022, more than 166 million farmed poultry animals have been sacrificed in an attempt to control the spread of H5N1, a highly pathogenic avian influenza A (HPAI) featuring H5 hemagglutinin and N1 neuraminidase surface proteins (H5N1).
STIs: New Vaccines and Expanding Recommendations
The incidence and prevalence of STIs remain high, and the serious health consequences of contracting one make prevention a national imperative.
Travel Vaccines: What’s Needed and Why?
Protecting Americans against severe disease significantly reduces their chances of getting seriously sick while traveling abroad.
Vaccine Advisers Recommend New RSV Vaccine for Infants
A group of outside advisers to the Centers for Disease Control and Prevention (CDC) voted 5-2 to recommend the use of Merck’s new antibody vaccine, Enflonsia (clesrovimab), that can protect babies from respiratory syncytial virus (RSV).
New Influenza Vaccine Provides Long-Lasting Protection and Higher Efficacy
A new clinical trial shows a single shot of a long-lasting influenza (flu) drug may protect people for an entire season, and it might do so more effectively than vaccines.
COVID-19-Influenza Combination and Standalone Influenza Vaccines Generated a Strong Immune Response
In a late-stage trial, Novavax’s experimental COVID-19-influenza combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) vaccines generated a strong immune response in adults aged 65 and older, similar to already approved vaccines against the viruses.
Novavax’s COVID-19 Vaccine Approved for Older Adults and At-Risk Individuals
After a six-week delay, the U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but only for people 65 and older and those 12 years and older who have at least one underlying condition, such as asthma, diabetes, lung disease, obesity and pregnancy, that puts them at higher risk of severe illness.